Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 12/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP2J2 | P51589 | 3/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10184497 | 0.90 | CHRM4 (0.46) | EPHX2CHRM4CYP2C9CYP2J2CCR1 | |
| SCHEMBL10186242 | 0.90 | CHRM4 (0.45) | USP5HDAC6EPHX2CHRM4CYP2C9 | |
| SCHEMBL10186245 | 0.88 | CHRM4 (0.44) | USP5HDAC6EPHX2CHRM4CYP2C9 | |
| SCHEMBL10185645 | 0.86 | CHRM4 (0.45) | USP5HDAC6EPHX2CHRM4CCR1 | |
| SCHEMBL10186215 | 0.86 | EPHX2 (0.49) | USP5EPHX2CHRM4CYP2C9CYP2J2 | |
| SCHEMBL10185026 | 0.84 | HRH3 (0.44) | CHRM4HRH3 | |
| SCHEMBL10186249 | 0.83 | CCR1 (0.45) | USP5EPHX2CHRM4CYP2C9CYP2J2 | |
| SCHEMBL10186184 | 0.83 | ALDH1A1 (0.44) | HRH3 | |
| SCHEMBL10185393 | 0.82 | HRH3 (0.42) | USP5HDAC6HRH3 | |
| SCHEMBL10186297 | 0.81 | SMN1; SMN2 (0.49) | USP5EPHX2CHRM4HRH3CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | USP5 3672/4885HDAC6 1314/4885EPHX2 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.